2024
Postacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review
Miller C, Borre C, Green A, Funaro M, Oliveira C, Iwasaki A. Postacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review. American Journal Of Medicine Open 2024, 12: 100078. DOI: 10.1016/j.ajmo.2024.100078.Peer-Reviewed Original ResearchClinical epidemiologyPost-acute sequelae of COVID-19High risk of biasLack of standardized definitionsPost-acute sequelaeRisk of biasSequelae of COVID-19United StatesScoping reviewComprehensive literature searchUS childrenShort follow-up durationFollow-up durationInclusion criteriaFemale sexOlder ageRisk factorsSARS-CoV-2 infectionLiterature searchChest painHigh riskOptimal preventionPediatric patientsPersistent symptomsCOVID-19Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis
Aparicio C, Willis Z, Nakamura M, Wolf J, Little C, Maron G, Sue P, Anosike B, Miller C, Bio L, Singh P, James S, Oliveira C. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis. Journal Of The Pediatric Infectious Diseases Society 2024, 13: 352-362. PMID: 38780125, PMCID: PMC11519042, DOI: 10.1093/jpids/piae052.Peer-Reviewed Original ResearchOdds ratioCritical COVID-19Absolute riskMeta-analysisSystematic reviewRisk stratificationConfidence intervalsInvasive mechanical ventilation requirementRisk factorsEstimate pooled odds ratiosSignificant ORsKey risk factorsPooled odds ratioCritical diseaseIntensive care unit admissionStatistically significant ORsMechanical ventilation requirementRandom-effects modelRisk of critical diseaseChronic pulmonary conditionsHealth conditionsIndependent reviewersPooled ORInclusion criteriaCOVID-19Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Willis Z, Oliveira C, Abzug M, Anosike B, Ardura M, Bio L, Boguniewicz J, Chiotos K, Downes K, Grapentine S, Hersh A, Heston S, Hijano D, Huskins W, James S, Jones S, Lockowitz C, Lloyd E, MacBrayne C, Maron G, McDonough M, Miller C, Morton T, Olivero R, Orscheln R, Schwenk H, Singh P, Soma V, Sue P, Vora S, Nakamura M, Wolf J. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. Journal Of The Pediatric Infectious Diseases Society 2024, 13: 159-185. PMID: 38339996, PMCID: PMC11494238, DOI: 10.1093/jpids/piad116.Peer-Reviewed Original ResearchConceptsRisk factorsRisk stratificationPediatric intensive care medicineEffects of therapyNon-hospitalized childrenPediatric infectious diseasesSevere COVID-19Cases of infectionMeta-analysis of dataIntensive care medicineClinical characteristicsPreventive therapyPediatric populationManagement of COVID-19Fatal infectionConsensus statementSevere illnessTherapyMeta-analysisTherapeutic interventionsSARS-CoV-2Expert consensusCare medicineRe-convenedGuidance statements
2021
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents
Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, Dulek DE, Waghmare A, Olivero R, Downes KJ, James SH, Pinninti SG, Yarbrough A, Aldrich ML, MacBrayne CE, Soma VL, Grapentine SP, Oliveira CR, Hayes M, Kimberlin DW, Jones SB, Bio LL, Morton TH, Hankins JS, Marόn-Alfaro G, Timberlake K, Young JL, Orscheln RC, Schwenk HT, Goldman DL, Groves HE, Huskins WC, Rajapakse NS, Lamb GS, Tribble AC, Lloyd E, Hersh AL, Thorell EA, Ratner AJ, Chiotos K, Nakamura MM. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. Journal Of The Pediatric Infectious Diseases Society 2021, 10: 629-634. PMID: 33388760, PMCID: PMC7799019, DOI: 10.1093/jpids/piaa175.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyHigh-risk groupAntibody therapyEmergency use authorizationCOVID-19Moderate coronavirus disease 2019Pediatric intensive care medicinePediatric-specific evidenceTreatment of mildPediatric infectious diseasesHigh-quality evidenceCoronavirus disease 2019Intensive care medicineSeries of teleconferencesREGN-COV2Infusion reactionsPediatric HematologyTimely administrationRisk factorsRoutine administrationDisease 2019Severe diseaseCare medicineHigh riskModest benefit
2016
Influenza-like illness in an urban community of Salvador, Brazil: incidence, seasonality and risk factors
Oliveira CR, Costa GSR, Paploski IAD, Kikuti M, Kasper AM, Silva MMO, Tavares AS, Cruz JS, Queiroz TL, Lima HCAV, Calcagno J, Reis MG, Weinberger DM, Shapiro ED, Ko AI, Ribeiro GS. Influenza-like illness in an urban community of Salvador, Brazil: incidence, seasonality and risk factors. BMC Infectious Diseases 2016, 16: 125. PMID: 26975185, PMCID: PMC4791800, DOI: 10.1186/s12879-016-1456-8.Peer-Reviewed Original ResearchConceptsInfluenza-like illnessYears of ageAcute febrile illnessAnnual incidenceRisk of ILIChildren 5Year oldsIncidence of ILIMean annual incidenceEpidemiology of influenzaCommunity-based surveillanceNegative test resultsSeasonal influenza transmissionILI peakMethodsBetween 2009Febrile illnessSore throatRegression modelsDisease burdenRisk factorsSchool-aged childrenEmergency unitInfluenza transmissionSignificant burdenYoung school-age children